Total Payments
$1.3M
2024 Payments
$228,957
Companies
20
Transactions
1,781
Medicare Patients
309
Medicare Billing
$148,106
Payment Breakdown by Category
Other$998,518 (77.5%)
Travel$137,994 (10.7%)
Consulting$115,321 (9.0%)
Food & Beverage$36,157 (2.8%)
Education$18.87 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $998,519 | 392 | 77.5% |
| Travel and Lodging | $137,994 | 684 | 10.7% |
| Consulting Fee | $115,321 | 35 | 9.0% |
| Food and Beverage | $36,157 | 667 | 2.8% |
| Education | $18.87 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $702,176 | 818 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $286,403 | 549 | $0 (2024) |
| ITI, Inc. | $111,537 | 163 | $0 (2023) |
| Axsome Therapeutics, Inc. | $58,478 | 55 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53,817 | 42 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $46,991 | 56 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $12,316 | 12 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $7,882 | 15 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $3,819 | 16 | $0 (2022) |
| Biogen, Inc. | $1,535 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $228,957 | 306 | Janssen Pharmaceuticals, Inc ($72,098) |
| 2023 | $275,075 | 370 | Janssen Pharmaceuticals, Inc ($104,277) |
| 2022 | $224,583 | 400 | Janssen Pharmaceuticals, Inc ($97,580) |
| 2021 | $129,197 | 178 | Alkermes, Inc. ($107,346) |
| 2020 | $70,799 | 102 | Alkermes, Inc. ($64,215) |
| 2019 | $121,906 | 162 | Alkermes, Inc. ($121,653) |
| 2018 | $128,208 | 130 | Alkermes, Inc. ($127,639) |
| 2017 | $109,284 | 133 | Alkermes, Inc. ($105,291) |
All Payment Transactions
1,781 individual payment records from CMS Open Payments — Page 1 of 72
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $121.73 | General |
| Category: Neuroscience | ||||||
| 12/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $58.16 | General |
| Category: Neuroscience | ||||||
| 12/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $40.00 | General |
| Category: Neuroscience | ||||||
| 12/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | Cash or cash equivalent | $21.31 | General |
| Category: Neuroscience | ||||||
| 12/23/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Neuroscience | ||||||
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $151.02 | General |
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $758.28 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $134.40 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $72.36 | General |
| Category: Neuroscience | ||||||
| 12/18/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $29.61 | General |
| Category: CNS | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,860.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $1,370.07 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Consulting Fee | Cash or cash equivalent | $5,130.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $614.95 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $326.57 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,780.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $192.53 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.70 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,322.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,994.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/25/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $148.85 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 32 | 173 | $19,972 | $6,717 |
| 2022 | 8 | 149 | 656 | $263,354 | $57,286 |
| 2021 | 6 | 128 | 743 | $407,750 | $84,103 |
Total Patients
309
Total Services
1,572
Medicare Billing
$148,106
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 73 | $11,972 | $4,383 | 36.6% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 14 | 100 | $8,000 | $2,334 | 29.2% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 17 | 296 | $207,465 | $38,162 | 18.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 45 | 133 | $21,235 | $7,299 | 34.4% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2022 | 20 | 157 | $10,742 | $3,941 | 36.7% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 11 | 11 | $9,990 | $2,270 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $4,968 | $2,118 | 42.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 14 | $3,163 | $1,309 | 41.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 15 | $3,090 | $1,258 | 40.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 17 | 18 | $2,700 | $929.02 | 34.4% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 22 | 517 | $361,900 | $67,643 | 18.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 82 | $12,345 | $4,741 | 38.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 27 | $8,127 | $4,241 | 52.2% |
| 90867 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), initial delivery and management | Office | 2021 | 17 | 17 | $15,080 | $3,561 | 23.6% |
| 96138 | Psychological or neuropsychological test administration and scoring by technician, first 30 minutes | Office | 2021 | 19 | 81 | $6,480 | $2,283 | 35.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 17 | 19 | $3,818 | $1,635 | 42.8% |
About Dr. Heather Luing, MD
Dr. Heather Luing, MD is a Psychiatry healthcare provider based in Saint Augustine, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952477366.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Heather Luing, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $228,957 received in 2024. These payments were reported across 1,781 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($998,519).
As a Medicare-enrolled provider, Luing has provided services to 309 Medicare beneficiaries, totaling 1,572 services with total Medicare billing of $148,106. Data is available for 3 years (2021–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Saint Augustine, FL
- Active Since 11/28/2006
- Last Updated 10/22/2020
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1952477366
Products in Payments
- SPRAVATO (Drug) $286,226
- ARISTADA (Drug) $203,399
- CAPLYTA (Drug) $165,354
- Aristada 441 mg (Drug) $151,966
- LYBALVI (Drug) $147,018
- VIVITROL (Drug) $97,404
- Vivitrol 380 mg (Drug) $73,427
- Auvelity (Drug) $58,478
- UZEDY (Drug) $46,947
- Vivitrol (Drug) $20,025
- FANAPT (Drug) $12,316
- COBENFY (Drug) $6,356
- REXULTI (Drug) $3,672
- VNS - Symmetry (Device) $555.65
- NEUROSTAR TMS THERAPY (Device) $409.53
- INVEGA SUSTENNA (Drug) $376.90
- LATUDA (Drug) $280.93
- VRAYLAR (Drug) $280.91
- ABILIFY MAINTENA (Drug) $249.94
- INGREZZA (Drug) $148.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.